You just read:

CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas

News provided by

CytRx Corporation

04 Jan, 2017, 09:00 ET